CA-NITRO-SOFTWARE
18.5.2023 15:58:31 CEST | Business Wire | Press release
Nitro Software, a global leader in SaaS PDF, eSign and business document solutions, launched new document accessibility features as part of the latest release of Nitro PDF Pro, its flagship product. Driven by its mission to provide easy-to-use, inclusive and compliant technology for all people and organizations, Nitro teamed up with digital accessibility solution provider Level Access.
“Everyone deserves access to digital information, and that includes the more than 1.3 billion people globally who identify as having a disability,” says Jonathon Avila, Chief Accessibility Officer at Level Access. “It has been deeply rewarding to support Nitro in providing innovative solutions that contribute to a more accessible digital world.”
Why do organizations need tools to create accessible PDF documents?
Document accessibility features are used by people with a range of needs, including those who are blind or have low vision. For organizations, particularly in higher education and government, accessibility features have a far-reaching and long-term impact on goals including:
Inclusivity: All people, including people with disabilities, should be equipped with technology that enables their success. With document accessibility tools, people with disabilities can participate and contribute equitably in education, the professional world and their communities.
Recruiting: Meeting the needs of all employees is a key differentiator for organizations during the recruiting and hiring process. Companies that prioritize the accessibility of documents and other digital information are at an advantage when competing for diverse talent.
Compliance: Many organizations are legally required to procure technology that meets accessibility compliance standards.
How is Nitro making documents more accessible and inclusive?
The latest Nitro PDF Pro release provides an intuitive solution for a vast and growing market seeking reliable tools that ensure document accessibility, inclusivity and compliance.
“Whether permanent, temporary or situational, we are all likely to experience disabilities in our lives. Nitro is a diverse and inclusive company, and we are proud that our latest release of Nitro PDF Pro provides capabilities for equal access to PDFs in the workplace, classroom, at home and everywhere in between,” says Sam Thorpe, Nitro’s Chief Product Officer. “The partnership with Level Access has been exceptionally valuable to ensure the software we design is aligned to the accessibility needs of people and organizations around the world.”
New features and enhancements in the latest release of Nitro PDF Pro include:
-
Accessibility features making it fast and easy to create accessible, compliant PDFs, such as:
- Auto-tagging documents, tables and lists in a few simple steps
- Assigning accessibility tags, roles and reading order in tagged PDFs
- Managing artifacts
- Specifying human languages of tagged PDFs
- Embedding fonts
- Supplying alternate text
- Marking PDF/UA compliance
- Fresh new UI with a modern, easy-to-navigate experience
- Expanded list of language installers
To learn more about creating accessible and compliant PDFs, join Nitro and Level Access for an educational webinar on June 8, 2023.
Explore more of what’s new in the latest release of Nitro PDF Pro.
About Nitro Software
Nitro is a global SaaS leader in PDF document management and eSigning. Nitro’s Productivity Platform includes powerful PDF tools, digital workflow automation, highly secure eSigning and identity capabilities. Its analytics solution measures and quantifies ROI, usage and sustainability impact. With a best-in-class customer success team, Nitro supports more than 67% of the Fortune 500, 3 million licensed users and 13,000+ business customers across 157 countries. For more information: visit https://gonitro.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005546/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
